The Journal of Urology
Volume 182, Issue 6, Supplement , Pages S27-S31 , December 2009

Obesity and Benign Prostatic Hyperplasia: Clinical Connections, Emerging Etiological Paradigms and Future Directions

  • J. Kellogg Parsons

      Affiliations

    • Division of Urologic Oncology, Moores Cancer Center, University of California, San Diego and Section of Surgery, San Diego Veterans Affairs Medical Center, La Jolla, California
    • Corresponding Author InformationCorrespondence: Division of Urology, University of California-San Diego, 200 West Arbor Dr., No. 8897, San Diego, California 92103-8897 (telephone: 619-543-2630; FAX: 619-543-6573)
    • Financial interest and/or other relationship with American Medical Systems.
    • ,
  • Aruna V. Sarma

      Affiliations

    • Department of Epidemiology, Ann Arbor, Michigan
    • Department of Urology, Ann Arbor, Michigan
    • ,
  • Kevin McVary

      Affiliations

    • Department of Urology, Northwestern University, Chicago, Illinois
    • Financial interest and/or other relationship with GlaxoSmithKline, Pfizer, Lilly/ICOS, Sanofi-Aventis, Allergan and National Institute of Diabetes and Digestive and Kidney Diseases.
    • ,
  • John T. Wei

      Affiliations

    • Department of Urology, Ann Arbor, Michigan
    • Financial interest and/or other relationship with Sanofi, American Medical Systems, Envisioneering, Gen-Probe and Beckman.

References 

  1. Wei JT, Calhoun E, Jacobsen SJ, et al. Urologic Diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256
  2. Engstrom G, Henningsohn L, Steineck G, et al. Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. BJU Int. 2005;95:810
  3. Engstrom G, Henningsohn L, Walker-Engstrom ML, et al. Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol. 2006;40:485
  4. Taylor BC, Wilt TJ, Fink HA, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006;68:804
  5. Parsons JK, Mougey J, Lambert L, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009;104:63
  6. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395
  7. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108:1541
  8. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387
  9. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 1999;53:473
  10. Soygur T, Kupeli B, Aydos K, et al. Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol. 1996;28:55
  11. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562
  12. Joseph MA, Wei JT, Harlow SD, et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate. 2002;53:322
  13. Lee S, Min HG, Choi SH, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring). 2006;14:172
  14. Sarma AV, Jaffe CA, Schottenfeld D, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology. 2002;59:362
  15. Freedland SJ, Platz EA, Presti JC, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006;175:500
  16. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140:989
  17. Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168:599
  18. Kristal AR, Arnold KB, Schenk JM, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. J Urol. 2007;177:1395
  19. Zucchetto A, Tavani A, Dal Maso L, et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes (Lond). 2005;29:798
  20. Burke JP, Rhodes T, Jacobson DJ, et al. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol. 2006;164:41
  21. Fritschi L, Tabrizi J, Leavy J, et al. Risk factors for surgically treated benign prostatic hyperplasia in Western Australia. Public Health. 2007;121:781
  22. Gupta A, Gupta S, Pavuk M, et al. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology. 2006;68:1198
  23. Rohrmann S, Smit E, Giovannucci E, et al. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004;159:390
  24. Seim A, Hoyo C, Ostbye T, et al. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int. 2005;96:88
  25. Haidinger G, Temml C, Schatzl G, et al. Risk factors for lower urinary tract symptoms in elderly men. Eur Urol. 2000;37:413
  26. Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157:906
  27. Wong SY, Woo J, Hong A, et al. Risk factors for lower urinary tract symptoms in southern Chinese men. Urology. 2006;68:1009
  28. Gann PH, Hennekens CH, Longcope C, et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;26:40
  29. Platz EA, Kawachi I, Rimm EB, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med. 1998;158:2349
  30. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935
  31. Hong J, Kwon S, Yoon H, et al. Risk factors for benign prostatic hyperplasia in South Korean men. Urol Int. 2006;76:11
  32. Dal Maso L, Zucchetto A, Tavani A, et al. Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer. 2006;118:2632
  33. Rohrmann S, Crespo CJ, Weber JR, et al. Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health and Nutrition Examination Survey. BJU Int. 2005;96:77
  34. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228
  35. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549
  36. Public health and aging: trends in aging—United States and worldwide. MMWR Morb Mortal Wkly Rep. 2003;52:101
  37. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752
  38. Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999;84:976
  39. Theyer G, Kramer G, Assmann I, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96
  40. Anim JT, Udo C, John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem. 1998;100:439
  41. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164
  42. Rohrmann S, De Marzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27
  43. St Sauver JL, Jacobson DJ, McGree ME, et al. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164:760

PII: S0022-5347(09)01834-5

doi: 10.1016/j.juro.2009.07.086

The Journal of Urology
Volume 182, Issue 6, Supplement , Pages S27-S31 , December 2009

Article Tools